# Study to Assess the Safety and Change in Disease Symptoms of Risankizumab (Skyrizi) in Adult Participants With Moderate to Severe Plaque Psoriasis and Psoriatic Arthritis

> **NCT04433442** · — · COMPLETED · sponsor: **AbbVie** · enrollment: 2324 (actual)

## Conditions studied

- Psoriasis
- Psoriatic Arthritis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04433442
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-04
- **Primary completion:** 2025-06-13
- **Final completion:** 2025-06-13
- **Target enrollment:** 2324 (ACTUAL)
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04433442

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04433442, "Study to Assess the Safety and Change in Disease Symptoms of Risankizumab (Skyrizi) in Adult Participants With Moderate to Severe Plaque Psoriasis and Psoriatic Arthritis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04433442. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*